BioKangtai - Public Comps and Valuation Multiples

BioKangtai Overview

About BioKangtai

Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.

Founded

1992

HQ

Employees

n/a

Website

biokangtai.com

Sectors

Vaccines & Immunotherapies
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $419M

LTM EBITDA $127M

EV

$2.5B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

BioKangtai Financials

BioKangtai has a last 12-month revenue of $419M and a last 12-month EBITDA of $127M.

In the most recent fiscal year, BioKangtai achieved revenue of $479M and an EBITDA of $173M.

BioKangtai expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BioKangtai valuation multiples based on analyst estimates

BioKangtai P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$479M	$400M	XXX	XXX	XXX
Gross Profit	$367M	$366M	XXX	XXX	XXX
Gross Margin	77%	91%	XXX	XXX	XXX
EBITDA	$173M	$115M	XXX	XXX	XXX
EBITDA Margin	36%	29%	XXX	XXX	XXX
Net Profit	$174M	-$18.3M	XXX	XXX	XXX
Net Margin	36%	-5%	XXX	XXX	XXX
Net Debt	n/a	$161M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

BioKangtai Stock Performance

As of April 15, 2025, BioKangtai's stock price is CNY 15 (or $2).

BioKangtai has current market cap of CNY 16.3B (or $2.2B), and EV of CNY 18.1B (or $2.5B).

See BioKangtai trading valuation data

BioKangtai Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.5B	$2.2B	XXX	XXX	XXX	XXX	$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

BioKangtai Valuation Multiples

As of April 15, 2025, BioKangtai has market cap of $2.2B and EV of $2.5B.

BioKangtai's trades at 6.0x LTM EV/Revenue multiple, and 19.7x LTM EBITDA.

Analysts estimate BioKangtai's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for BioKangtai and 10K+ public comps

BioKangtai Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$2.5B	XXX	XXX	XXX
EV/Revenue	6.2x	XXX	XXX	XXX
EV/EBITDA	21.7x	XXX	XXX	XXX
P/E	44.1x	XXX	XXX	XXX
P/E/Growth	1.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioKangtai Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

BioKangtai Valuation Multiples

BioKangtai's NTM/LTM revenue growth is 14%

BioKangtai's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, BioKangtai's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate BioKangtai's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for BioKangtai and other 10K+ public comps

BioKangtai Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	-16%	XXX	XXX	XXX	XXX
EBITDA Margin	29%	XXX	XXX	XXX	XXX
EBITDA Growth	-33%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	43%	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	n/a	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	34%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	4%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	14%	XXX	XXX	XXX	XXX
Opex to Revenue	54%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry